Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development	$ 4,944	$ 5,041	$ 10,428	$ 9,220
General and administrative	2,833	1,191	5,154	2,782
Total operating expenses	7,777	6,232	15,582	12,002
Loss from operations	(7,777)	(6,232)	(15,582)	(12,002)
Other income (expense)
Change in fair value of warrant liability	(23)	0	(23)	0
Change in fair value of embedded derivatives	321	0	429	74
Gain on extinguishment of promissory notes payable	604	0	604	0
Foreign exchange transaction gain	(9)	0	(9)	0
Interest income	39	0	51	1
Interest expense	(714)	(1,067)	(1,056)	(2,432)
Total other income (expense)	218	(1,067)	(4)	(2,357)
Net loss	(7,559)	(7,299)	(15,586)	(14,359)
Other comprehensive loss:
Foreign currency translation adjustment	(2)	0	(2)	0
Comprehensive loss	$ (7,561)	$ (7,299)	$ (15,588)	$ (14,359)
Net loss per common share, basic (in dollars per share)	$ (2.44)	$ (23.20)	$ (9.06)	$ (45.85)
Net loss per common share, diluted (in dollars per share)	$ (2.44)	$ (23.20)	$ (9.06)	$ (45.85)
Weighted average common shares outstanding, basic (in shares)	3,100,957	314,572	1,720,202	313,148
Weighted average common shares outstanding, diluted (in shares)	3,100,957	314,572	1,720,202	313,148